Serum neurofilament light chain concentration in a phase 1/2 trial of autologous mesenchymal stem cell transplantation

• Published in: Multiple sclerosis journal - experimental, translational and clinical translational and clinical, 2019-10, Vol.5 (4), p.2055217319887198-2055217319887198
• Main Authors: Baldassari, Laura E, Planchon, Sarah M, Bermel, Robert A, Nakamura, Kunio, Fisher, Elizabeth, Feng, Jenny, Sakaie, Ken E, Ontaneda, Daniel, Cohen, Jeffrey A
• Format: Article
• Language: English
• Subjects: Light; Multiple sclerosis; NMR; Nuclear magnetic resonance; Original Research Paper; Stem cells; Transplants & implants
• ISSN: 2055-2173; 2055-2173
• DOI: 10.1177/2055217319887198

Background Serum neurofilament light chain concentration is a proposed biomarker of axonal injury in multiple sclerosis. Mesenchymal stem cells have anti-inflammatory and repair-promoting activities, making them of interest for potential multiple sclerosis treatment. Objectives The purpose of this study was to assess correlation of serum neurofilament light chain concentration and measures of multiple sclerosis disease activity/severity, longitudinal stability of serum neurofilament light chain concentration, and treatment effect of mesenchymal stem cell transplantation on serum neurofilament light chain concentration. Methods Twenty-four multiple sclerosis patients underwent intravenous infusion of autologous mesenchymal stem cells. Clinical assessments, serum collection, and brain magnetic resonance imaging were performed at months –1, 0 (transplant), 1, 3, and 6. Matched control serum was collected once (n = 10). Serum neurofilament light chain concentration was measured by single-molecule array. Serum neurofilament light chain concentration correlations with disease measures were analyzed by Spearman correlations and linear mixed effect models. Pre-post transplant serum neurofilament light chain concentration was compared by Wilcoxon signed rank testing. Results There were significant (p